Pre-trial
Protocol IQ
Protocol design optimizer · simulate I/E changes · amendment-risk forecast
Protocols active
8
across portfolio
Amendments YTD
11
across all programs
Avg complexity
68
0-100 score (industry median: 62)
Predicted SFR
22%
weighted avg screen-fail rate
Protocol Agent · complexity & amendment risk
For active protocols, Continuum scores design complexity from I/E criteria density, visit burden, and historical amendment patterns in similar trials. 3 protocols flagged as high amendment risk based on comparable-trial telemetry.
Protocols under design / amendment
Hover for amendment-risk forecastCSL-SCD-005Phase 2Sickle Cell
CSL324 in Sickle Cell Disease — Phase 2a
Complexity
58
Amend risk
LowCSL-HAE-012Phase 2HAE
Oral HAE prophylactic — Phase 2 dose-finding
Complexity
59
Amend risk
LowCSL-RES-009Phase 2Respiratory
CSL787 in Cystic Fibrosis — Phase 2
Complexity
60
Amend risk
LowCSL-HEM-938Hematology
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Complexity
68
Amend risk
LowCSL-HEM-021Phase 3Hematology / Gene Therapy
CSL824 — Gene Therapy for Hemophilia A (Phase 3 pivotal)
Complexity
66
Amend risk
HighCSL-IRD-031Phase 3Iron / Nephrology
Ferinject in CKD anemia — head-to-head Phase 3
Complexity
68
Amend risk
HighCSL-HAE-007Phase 4HAE
ANDEMBRY-NextGen — pediatric indication expansion (Phase 4)
Complexity
63
Amend risk
MediumCSL-IMM-203Phase 3Immunology
IgPro20 in CIDP — long-term extension
Complexity
64
Amend risk
MediumProtocol Agent · Sonnet 4.5 · simulates I/E changes · predicts amendment likelihood